Literature DB >> 29670706

Conformationally Constrained Cinnolinone Nucleoside Analogues as Siderophore Biosynthesis Inhibitors for Tuberculosis.

Surendra Dawadi1, Helena I M Boshoff2, Sae Woong Park3, Dirk Schnappinger3, Courtney C Aldrich1.   

Abstract

5'-O-[N-(Salicyl)sulfamoyl]adenosine (Sal-AMS, 1) is a nucleoside antibiotic that inhibits incorporation of salicylate into siderophores required for bacterial iron acquisition and has potent activity against Mycobacterium tuberculosis (Mtb). Cinnolone analogues exemplified by 5 were designed to replace the acidic acyl-sulfamate functional group of 1 (pKa = 3) by a more stable sulfonamide linkage (pKa = 6.0) in an attempt to address potential metabolic liabilities and improve membrane permeability. We showed 5 potently inhibited the mycobacterial salicylate ligase MbtA (apparent Ki = 12 nM), blocked production of the salicylate-capped siderophores in whole-cell Mtb, and exhibited excellent antimycobacterial activity under iron-deficient conditions (minimum inhibitor concentration, MIC = 2.3 μM). To provide additional confirmation of the mechanism of action, we demonstrated the whole-cell activity of 5 could be fully antagonized by the addition of exogenous salicylate to the growth medium. Although the total polar surface area (tPSA) of 5 still exceeds the nominal threshold value (140 Å) typically required for oral bioavailability, we were pleasantly surprised to observe introduction of the less acidic and conformationally constrained cinnolone moiety conferred improved drug disposition properties as evidenced by the 7-fold increase in volume of distribution in Sprague-Dawley rats.

Entities:  

Year:  2018        PMID: 29670706      PMCID: PMC5900334          DOI: 10.1021/acsmedchemlett.8b00090

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  31 in total

1.  Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis of Mycobacterium tuberculosis.

Authors:  Ravindranadh V Somu; Helena Boshoff; Chunhua Qiao; Eric M Bennett; Clifton E Barry; Courtney C Aldrich
Journal:  J Med Chem       Date:  2006-01-12       Impact factor: 7.446

2.  Design, synthesis, and biological evaluation of beta-ketosulfonamide adenylation inhibitors as potential antitubercular agents.

Authors:  Jagadeshwar Vannada; Eric M Bennett; Daniel J Wilson; Helena I Boshoff; Clifton E Barry; Courtney C Aldrich
Journal:  Org Lett       Date:  2006-10-12       Impact factor: 6.005

3.  Separable roles for Mycobacterium tuberculosis ESX-3 effectors in iron acquisition and virulence.

Authors:  JoAnn M Tufariello; Jessica R Chapman; Christopher A Kerantzas; Ka-Wing Wong; Catherine Vilchèze; Christopher M Jones; Laura E Cole; Emir Tinaztepe; Victor Thompson; David Fenyö; Michael Niederweis; Beatrix Ueberheide; Jennifer A Philips; William R Jacobs
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-04       Impact factor: 11.205

Review 4.  Iron and microbial infection.

Authors:  Ulrich E Schaible; Stefan H E Kaufmann
Journal:  Nat Rev Microbiol       Date:  2004-12       Impact factor: 60.633

5.  Investigation and conformational analysis of fluorinated nucleoside antibiotics targeting siderophore biosynthesis.

Authors:  Surendra Dawadi; Kishore Viswanathan; Helena I Boshoff; Clifton E Barry; Courtney C Aldrich
Journal:  J Org Chem       Date:  2015-04-30       Impact factor: 4.354

6.  Iron acquisition by Mycobacterium tuberculosis: isolation and characterization of a family of iron-binding exochelins.

Authors:  J Gobin; C H Moore; J R Reeve; D K Wong; B W Gibson; M A Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

Review 7.  Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome.

Authors:  Helen McIlleron; Graeme Meintjes; William J Burman; Gary Maartens
Journal:  J Infect Dis       Date:  2007-08-15       Impact factor: 5.226

8.  Disruption of mycobactin biosynthesis leads to attenuation of Mycobacterium tuberculosis for growth and virulence.

Authors:  P Vineel Reddy; Rupangi Verma Puri; Priyanka Chauhan; Ritika Kar; Akshay Rohilla; Aparna Khera; Anil K Tyagi
Journal:  J Infect Dis       Date:  2013-06-20       Impact factor: 5.226

9.  The promoter of Rv0560c is induced by salicylate and structurally-related compounds in Mycobacterium tuberculosis.

Authors:  Dorothée L Schuessler; Tanya Parish
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

10.  Lipidomic analysis links mycobactin synthase K to iron uptake and virulence in M. tuberculosis.

Authors:  Cressida A Madigan; Amanda Jezek Martinot; Jun-Rong Wei; Ashoka Madduri; Tan-Yun Cheng; David C Young; Emilie Layre; Jeffrey P Murry; Eric J Rubin; D Branch Moody
Journal:  PLoS Pathog       Date:  2015-03-27       Impact factor: 6.823

View more
  7 in total

1.  Integrated Target-Based and Phenotypic Screening Approaches for the Identification of Anti-Tubercular Agents That Bind to the Mycobacterial Adenylating Enzyme MbtA.

Authors:  Lindsay Ferguson; Geoff Wells; Sanjib Bhakta; James Johnson; Junitta Guzman; Tanya Parish; Robin A Prentice; Federico Brucoli
Journal:  ChemMedChem       Date:  2019-09-23       Impact factor: 3.466

2.  Gram-scale preparation of the antibiotic lead compound salicyl-AMS, a potent inhibitor of bacterial salicylate adenylation enzymes.

Authors:  Nihar Kinarivala; Lisa C Standke; Tezcan Guney; Cheng Ji; Naoyoshi Noguchi; Yasutomi Asano; Derek S Tan
Journal:  Methods Enzymol       Date:  2020-05-05       Impact factor: 1.600

Review 3.  Targeting adenylate-forming enzymes with designed sulfonyladenosine inhibitors.

Authors:  Michaelyn C Lux; Lisa C Standke; Derek S Tan
Journal:  J Antibiot (Tokyo)       Date:  2019-04-15       Impact factor: 2.649

4.  Structure-Based Design, Synthesis, and Biological Evaluation of Non-Acyl Sulfamate Inhibitors of the Adenylate-Forming Enzyme MenE.

Authors:  Christopher E Evans; Yuanyuan Si; Joe S Matarlo; Yue Yin; Jarrod B French; Peter J Tonge; Derek S Tan
Journal:  Biochemistry       Date:  2019-03-26       Impact factor: 3.162

Review 5.  Advances in Key Drug Target Identification and New Drug Development for Tuberculosis.

Authors:  Jie Mi; Wenping Gong; Xueqiong Wu
Journal:  Biomed Res Int       Date:  2022-02-25       Impact factor: 3.411

Review 6.  Analogues of Pyrimidine Nucleosides as Mycobacteria Growth Inhibitors.

Authors:  Liudmila A Alexandrova; Anastasia L Khandazhinskaya; Elena S Matyugina; Dmitriy A Makarov; Sergey N Kochetkov
Journal:  Microorganisms       Date:  2022-06-27

7.  Rational inhibitor design for Pseudomonas aeruginosa salicylate adenylation enzyme PchD.

Authors:  Catherine L Shelton; Kathleen M Meneely; Trey A Ronnebaum; Annemarie S Chilton; Andrew P Riley; Thomas E Prisinzano; Audrey L Lamb
Journal:  J Biol Inorg Chem       Date:  2022-05-05       Impact factor: 3.862

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.